RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RegeneRx Biopharmaceuticals Stock

RegeneRx Biopharmaceuticals P/S 2024

RegeneRx Biopharmaceuticals P/S

336.62

Ticker

RGRX

ISIN

US75886X1081

WKN

875295

As of Oct 7, 2024, RegeneRx Biopharmaceuticals's P/S ratio stood at 336.62, a -33.42% change from the 505.55 P/S ratio recorded in the previous year.

The RegeneRx Biopharmaceuticals P/S history

RegeneRx Biopharmaceuticals Aktienanalyse

What does RegeneRx Biopharmaceuticals do?

RegeneRx Biopharmaceuticals Inc is a biotechnology company focused on the development and commercialization of drugs for the treatment of diseases. The company is headquartered in Rockville, Maryland and was founded in 1982. Since its inception, RegeneRx has brought various products to market and is known for its research in tissue regeneration. The company started its early years with research in the field of nerve regeneration. As a result of this research, RegeneRx developed its first chemical called Thymosin beta 4 (Tβ4). Tβ4 is a naturally occurring protein produced in the human body. It serves as a growth factor for cells and plays an important role in healing damaged tissue. RegeneRx used this knowledge and began intensive work on the growth of Tβ4 in the laboratory. The company's researchers soon realized that Tβ4 was not only important for nerve regeneration, but could also be used in skin damage, stroke, and heart attack treatment. The researchers continued to work on the substance and in 1999 successfully brought the so-called Eye Drop product A3G12 to the market. This product is used to treat eye injuries and infections. In the following years, RegeneRx continued to research Tβ4. It was found that Tβ4 could also be successfully used in COPD (Chronic Lung Problems), wound healing, and bone disorders. Various products were developed for this purpose, available under the names RGN-137, RGN-259, and RGN-352. RegeneRx has also formed partnerships with other pharmaceutical companies such as Axio Biosolutions and Gtree BNP, and has successfully collaborated with them. In early 2021, it was decided that RegeneRx would expand its expertise in the Asian market and signed an agreement with Gtree BNP. The two companies planned to market RegeneRx products RGN-503 and RGN-352 in South Korea. Overall, RegeneRx Biopharmaceuticals Inc. has developed an impressive list of products that have successfully undergone patent and regulatory processes. These products treat a variety of diseases and injuries. RegeneRx is committed to continuing its research in this field and developing new products to help improve the health and well-being of patients worldwide. The company's business model primarily focuses on research and development. It has expanded in recent years due to the high potential of Tβ4 and its use in many medical areas. RegeneRx expects that by expanding the use of Tβ4, there will be greater acceptance and demand for its products worldwide. RegeneRx Biopharmaceuticals Inc is a company operating in the field of regenerative medicine. The products are typically positioned in the higher price range, in line with the company's market positioning. The company has successfully collaborated with other pharmaceutical companies in the past and is expected to form further alliances. RegeneRx sees itself as a leading biotechnology company focused on innovative drugs. RegeneRx Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding RegeneRx Biopharmaceuticals's P/S Ratio

RegeneRx Biopharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing RegeneRx Biopharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating RegeneRx Biopharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in RegeneRx Biopharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about RegeneRx Biopharmaceuticals stock

What is the price-to-earnings ratio of RegeneRx Biopharmaceuticals?

The price-earnings ratio of RegeneRx Biopharmaceuticals is currently 336.62.

How has the price-earnings ratio of RegeneRx Biopharmaceuticals changed compared to last year?

The price-to-earnings ratio of RegeneRx Biopharmaceuticals has increased by -33.42% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of RegeneRx Biopharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of RegeneRx Biopharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of RegeneRx Biopharmaceuticals affect the company?

An increase in the price-earnings ratio of RegeneRx Biopharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of RegeneRx Biopharmaceuticals affect the company?

A decrease in the price-earnings ratio of RegeneRx Biopharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of RegeneRx Biopharmaceuticals?

Some factors that influence the price-earnings ratio of RegeneRx Biopharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does RegeneRx Biopharmaceuticals pay?

Over the past 12 months, RegeneRx Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RegeneRx Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of RegeneRx Biopharmaceuticals?

The current dividend yield of RegeneRx Biopharmaceuticals is .

When does RegeneRx Biopharmaceuticals pay dividends?

RegeneRx Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of RegeneRx Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RegeneRx Biopharmaceuticals located?

RegeneRx Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von RegeneRx Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RegeneRx Biopharmaceuticals from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did RegeneRx Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of RegeneRx Biopharmaceuticals in the year 2023?

In the year 2023, RegeneRx Biopharmaceuticals distributed 0 USD as dividends.

In which currency does RegeneRx Biopharmaceuticals pay out the dividend?

The dividends of RegeneRx Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RegeneRx Biopharmaceuticals

Our stock analysis for RegeneRx Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RegeneRx Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.